the aid library

LIST OPTIONS

Filter

2313

2019 Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline
recommended

World Health Organization WHO (2019) C_WHO

Of the 50 antibiotics in the pipeline, 32 target WHO priority pathogens but the majority have only limited benefits when compared to existing antibiotics. Two of these are active against the multi-drug resistant Gram-negative bacteria, which are spreading rapidly and require urgent solutions. Gr... more

Guidance on establishing national and local AMR surveillance systems in the Western Pacific Region

World Health Organization WHO (2024) C_WHO

Antimicrobial resistance (‎AMR)‎ is impacting our health, economies and development. Up to 5.2 million people may die because of resistant bacterial infections across the Western Pacific Region from 2020-2030. Childbirth, surgery, cancer ... and other interventions will become impossibly dangerous if bacterial infections no longer respond to available antibiotics. more

Depressants - Alcohol

UCLA Brain Research Institute (2021) CC

The pamphlet "Alcohol and Depressants" explains the effects of depressants, including alcohol. Depressants slow brain activity by increasing the release of inhibitory neurotransmitters like GABA, leading to effects such as sedation, decreased anxiety, and reduced heart rate. Alcohol, a legal depress... more

Interventions for Noncommunicable Diseases in Primary Health Care - online course

World Health Organization (WHO) World Health Organization (WHO) (2023) C_WHO

The OpenWHO course titled "Interventions for Noncommunicable Diseases in Primary Health Care" provides guidance on screening, detection, diagnosis, and management of major noncommunicable diseases (NCDs) such as cardiovascular diseases, type 2 diabetes, chronic respiratory diseases (asthma and chron... more

Download (290)

View PDF (386)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

External Link

Africa: cancer control Series

The Lancet (2013) C1

Sub-Saharan Africa faces a major public-health challenge from non-communicable diseases. Although infectious diseases continue to afflict Africa, the proportion of the overall disease burden in sub-Saharan Africa attributable to cancer is rising, an... more

External Link

Access to Cancer Therapeutics in Low- and Middle-Income Countries

Ruff, P.; Sana-Al-Sukhun, C. Blanchard, et al. (2016) C2

2016 ASCO EDUCATIONAL BOOK | asco.org/edbo

External Link

Availability, Affordability, Access, and Pricing of Anti-cancer Medicines in Low- and Middle-Income Countries: A Systematic Review of Literature

Ocran Mattila, P.; R. Ahmad, S.Shahzad Hasan, et al. (2021) C2

Front. Public Health, 30 April 2021 | https://doi.org/10.3389/fpubh.2021.628744

Download (159)

View PDF (166)

Standard treatment guidelines oncology India

Ministry of Health & Family Welfare, India (2020) C1

Accessed Febr. 6, 2020

Standard treatment guidelines urology (India)

Ministry of Health & Family Welfare, India (2020) C1

Accessed Febr. 6, 2020

Download (132)

View PDF (133)

National Cancer Handling Guidelines

Ministry of Health, Kenya (2020) C1

External Link

COVID-19 and its ramifications for cancer patients in low-resource settings: Ghana as a case study

Kugbey, N., N. Ohene-Oti and V. Vanderpuye (2020) CC

Download (202)

View PDF (185)

Cancer Advocacy Traning Toolkit for Africa

Godfrey, E. AfrOx; ESMO; et al. (2014) CC

One of the most important ways we feel we can help to reduce the burden of cancer in Africa is to work with African cancer advocacy organisations to help educate and advocate about ... in their countries. To this end in 2010 we designed with our partners, 13 posters for use in Africa giving health and lifestyle tips on how to avoid cancer and highlighting the early warning sign and symptoms of common cancers in Africa more

External Link

Cancer in sub-Saharan Africa
recommended

Ngwa, W.; et al. Lancet Oncology Commission (2022) C2

Lancet Oncol 2022; 23: e251–312Published OnlineMay 9, 2022 https://doi.org/10.1016/S1470-2045(21)00720-8 In sub-Saharan Africa (SSA), urgent action is needed to curb a growing crisis in cancer incidence and mortality. Without rapid interventions... more

Standard treatment guidelines gastrointestinal surgery (India)

Ministry of Health & Family Welfare, India (2020) C1

Accessed Febr. 6, 2020

Download (371)

View PDF (555)

Lesotho: Cancer Country Profiles

World Health Organization (WHO) (2014) C_WHO

Facts About Cancer in Uganda

Ministry of Health, The Republic of Uganda (2009) C_WHO

What you need to know about cancer and how to prevent it.

Download (1867)

View PDF (1404)

LEEP Clinical Standards of Practice

Pathfinder International (2013)

This manual guides trained health care providers through the LEEP procedure to remove precancerous cervical lesions that cannot be treated with cryotherapy in order to prevent cervical cancer. The Standard Operating Procedures describe the equipment... more

Panduan Penatalaksanaan Kanker Prostat

Umbas, R., S. Hardjowijoto, C.A. Mochtar, et al., Indonesian Urological Association (2011) C1

Guidelines for Therapy and Management of Prostate Cancer in Indonesia

Download (429)

View PDF (703)

Kanker Paru

The Indonesian Association of Pulmonologist (2003) C1

Guidelines for Diagnosis and Management of Lung Cancer in Indonesia

2019 Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline recommended

Cancer in sub-Saharan Africa recommended

2019 Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline
recommended

Cancer in sub-Saharan Africa
recommended